Table 1 The correlation between RPL21 expression and CRC clinicopathological characteristics
| Â | No. of cases | Highly expressed in invasive front? | Chi-squared value | p-Value | |
|---|---|---|---|---|---|
Yes | No | ||||
Frequency | 142 (100.0%) | 95 (66.9%) | 47 (33.1%) | Â | Â |
Age | |||||
 Younger (< 50 years) | 32 (22.5%) | 20 (62.5%) | 12 (37.5%) | 0.361 | 0.548 |
 Older (≥ 50 years) | 110 (77.5%) | 75 (68.2%) | 35 (31.8%) | ||
Gender | |||||
 Male | 87 (61.3%) | 60 (69.0%) | 27 (31.0%) | 0.432 | 0.511 |
 Female | 55 (38.7%) | 35 (63.6%) | 20 (36.4%) | ||
Position | |||||
 Colon | 102 (71.8%) | 70 (68.6%) | 32 (31.4%) | 0.487 | 0.485 |
 Rectum | 40 (28.2%) | 25 (62.5%) | 15 (37.5%) | ||
Tumor size (maximum diameter) | |||||
 < 5 cm | 70 (49.3%) | 45 (64.3%) | 25 (35.7%) | 0.427 | 0.514 |
 ≥ 5 cm | 72 (50.7%) | 50 (69.4%) | 22 (30.6%) | ||
Tumor grade (differentiation) | |||||
 G1 | 12 (8.5%) | 6 (50.0%) | 6 (50.0%) | 6.221 | 0.045 |
 G2 | 106 (74.6%) | 77 (72.6%) | 29 (27.4%) | ||
 G3 | 24 (16.9%) | 12 (50.0%) | 12 (50.0%) | ||
Invasive depth | |||||
 Submucosal | 3 (2.1%) | 0 (0.0%) | 3 (100.0%) | 9.457 | 0.024 |
 Myometrium | 16 (11.3%) | 8 (50.0%) | 8 (50.0%) | ||
 Subserosal | 90 (63.4%) | 62 (68.9%) | 28 (31.1%) | ||
 Break the serosa | 33 (23.2%) | 25 (75.8%) | 8 (24.2%) | ||
Mucinous component | |||||
 Absent | 127 (89.4%) | 88 (69.3%) | 39 (30.7%) | 3.101 | 0.078 |
 Present | 15 (10.6%) | 7 (46.7%) | 8 (53.3%) | ||
Microsatellite instability | |||||
 MSS | 119 (83.8%) | 81 (68.1%) | 38 (31.9%) | 1.105 | 0.575 |
 MSI-L | 8 (5.6%) | 4 (50.0%) | 4 (50.0%) | ||
 MSL-H | 15 (10.6%) | 10 (66.7%) | 5 (33.3%) | ||
Lymphatic metastasis | |||||
 Negative | 73 (51.4%) | 47 (64.4%) | 26 (35.6%) | 0.430 | 0.512 |
 Positive | 69 (48.6%) | 48 (69.6%) | 21 (30.4%) | ||
Distant metastasis | |||||
 Negative | 133 (93.7%) | 86 (64.7%) | 47 (35.3%) | 4.754 | 0.029 |
 Positive | 9 (6.3%) | 9 (100.0%) | 0 (0.0%) | ||